Home Tags Allergan
Dispensed: Pharma’s next big megamerger, a string of healthcare IPOs, and why the CEO of Clover Health regrets setting up shop in Silicon Valley...
Welcome to Dispensed, our weekly dispatch of healthcare, biotech, and pharma news from Business Insider.
Here's the history of how Botox went from an understudied toxin to a blockbuster drug used by millions.
Allergan started out as a tiny but beloved Southern California eye care firm before expanding to a $130 billion company. Here’s how the Botox-ma...
Here's how Allergan went from its start as a sleepy but beloved company out of Southern California in the 1950s to an acquisition target for AbbVie.
AbbVie expects the acquisition to generate at least $2 billion in pre-tax synergies and cost reductions within three years.
The biopharmaceuticals giant and drugmaker want to create a leader across immunology, neuroscience, eye care, and other medical fields.
A fresh crop of promising drugs is poised to change the way depression is treated for the first time in decades. Here are the ones to watch in 2019.
Researchers are on the hunt for better drugs to treat depression, a leading cause of disability worldwide. Promising options include ketamine and psilocybin.
Allergan is asking millennials if they’re ‘bo-curious,’ and it’s part of a plan to find a new generation of Botox customers
Allergan is plotting a handful of campaigns targeted at millennials who might be considering getting wrinkle treatments. They're asking youngsters if they're "bo-curious" and instructing them to "Juvederm It," in a bid to make its filler line a household name.
Stanford researchers are figuring out how ketamine fights depression — and why the drug has been called ‘the most important discovery in h...
A new Stanford study is the first to illuminate how ketamine works in the brain to alleviate depression. The research suggests that the drug engages the opioid system — the same one that's activated by opioid painkillers — in addition to affecting the glutamate system.
Allergan said on Tuesday that the Food and Drug Administration would not approve one of its women's health drugs, Esmya. The agency cited "safety concerns regarding Esmya post-marketing reports outside the United States," Allergan said.
Allergan should not look to pursue an ambitious M&A strategy at this time, the hedge funds said in a letter, and should instead focus on running its core business.